Acadian Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Acadian Asset Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-671,581	Closed	-$3.34M	–	2315
2021 Q1	$3.34M	Buy	671,581 +217,317	+48%	+$1.05M	0.01%	580
2020 Q4	$1.96M	Buy	454,264 +169,575	+60%	+$690K	0.01%	763
2020 Q3	$1.22M	Buy	284,689 +264,952	+1,342%	+$1.11M	0.01%	832
2020 Q2	$89K	Buy	+19,737	New	+$88.2K	﹤0.01%	1749
2017 Q2	–	Sell	-29,759	Closed	-$210K	–	1669
2017 Q1	$210K	Buy	29,759 +10,134	+52%	+$63.5K	﹤0.01%	1035
2016 Q4	$83K	Buy	19,625 +18,173	+1,252%	+$87.9K	﹤0.01%	1118
2016 Q3	$7K	Hold	1,452	–	–	﹤0.01%	1282
2016 Q2	$5K	Buy	1,452 +114	+9%	+$419	﹤0.01%	1309
2016 Q1	$5K	Sell	1,338 -2,474	-65%	-$8.74K	﹤0.01%	1281
2015 Q4	$13K	Buy	+3,812	New	+$17.7K	﹤0.01%	1199

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Acadian Asset Management's KIN Position: Q2 2021 in Review

Acadian Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 671,581 shares — an estimated $3.34M sold.

Acadian Asset Management first reported a position in KIN in Q4 2015 and held it in 10 quarters. The position peaked at $3.34M in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

Acadian Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
Acadian Asset Management sold 671,581 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $3.34M.
Acadian Asset Management first reported a position in Kindred Biosciences, Inc. in Q4 2015 and held it in 10 quarters.
Acadian Asset Management's Kindred Biosciences, Inc. position peaked at $3.34M in Q1 2021.
87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Acadian Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.